The glycosphingolipid inhibitor eliglustat inhibits autophagy in osteoclasts to increase bone mass and reduce myeloma bone disease (2021)
Attributed to:
University of Oxford Confidence in Concept – Round 7
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1101/2021.02.05.429906
Publication URI: http://dx.doi.org/10.1101/2021.02.05.429906
Type: Preprint